Advertisement

Risk Factors in Multiple Sclerosis-Implications for Pathogenesis

  • William A. Sibley
Part of the NATO ASI Series book series (NSSA, volume 142)

Abstract

Current evidence suggests that multiple sclerosis (MS) is an immunemediated illness occuring in genetically susceptible subjects, in response to some environmental agency. The argument in favor of the latter is compelling, and is derived mostly from well-known geographical differences in the prevalence of the illness, from migration studies, and from evidence of case clustering. Kurtzke concludes that these factors “serve to define MS as an acquired, exogenous, environmental disease (1).

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Stressful Life Event Swine Influenza Exacerbation Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. F. Kurtzke, The epidemiology of multiple sclerosis, in: “Multiple Sclerosis”, J. F. Hallpike, C. W. M. Adams, and W. W. Tourtellotte, eds., Williams and Wilkins, Baltimore (1983).Google Scholar
  2. 2.
    C. F. Bamford, W. A. Sibley, C. Thies, Trauma as an etiologic and aggravating factor in multiple sclerosis, Neurology, 31: 1229 (1981).CrossRefGoogle Scholar
  3. 3.
    C. R. Bamford, W. A. Sibley, and J. F. Laguna, Anesthesia in multiple sclerosis, Canad. J. Neurol. Sci., 5: 41 (1978).Google Scholar
  4. 4.
    W. A. Sibley, C. R. Bamford, and K. Clark, Clinical viral infections and multiple sclerosis, Lancet, 1: 1313 (1985).CrossRefGoogle Scholar
  5. 5.
    C. R. Bamford, W. A. Sibley, and J. F. Laguna, Swine influenza vaccination in patients with multiple sclerosis, Arch. Neurol., 35: 242 (1978).CrossRefGoogle Scholar
  6. 6.
    G. A. Schumacher, G. Beebe, R. F. Kibler, Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis, Ann. N.Y. Acad. Sci., 122: 552 (1965).CrossRefGoogle Scholar
  7. 7.
    J. F. Kurtzke, On the evaluation of disability in multiple sclerosis, Neurology, 11: 686 (1961).CrossRefGoogle Scholar
  8. 8.
    P. V. Rabins, B. R. Brooks, P. O’Donnell, Structural brain correlates of emotional disorder in multiple sclerosis, Brain, 109: 585 (1986).CrossRefGoogle Scholar
  9. 9.
    U. Jahnke, E. H. Fischer, and E. C. Alvord, Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis, Science, 229: 282 (1985).CrossRefGoogle Scholar
  10. 10.
    F. Rosa and M. Fellous, The effect of gamma interferon on major histocompatibility complex antigens, Immunol. Today, 5: 261 (1984).CrossRefGoogle Scholar
  11. 11.
    H. S. Panitch, A. S. Haley, R. L. Hirsch, A trial of gamma inerferon in multiple sclerosis: clinical results (abstract), Neurology, 36 (Suppl.l): 285 (1986).CrossRefGoogle Scholar
  12. 12.
    S. Narod, C. M. Johnson-Lussemburg, Q. Zheng, and R. Nelson, Viral infections and MS (letter), Lancet, 2: 165 (1985).CrossRefGoogle Scholar
  13. 13.
    W. A. Sibley and J. M. Foley, Infection and immunization in multiple sclerosis, Ann. N.Y. Acad. Sci., 122: 457 (1965).CrossRefGoogle Scholar
  14. 14.
    V. ter Meulen and J. R. Stephenson, The possible role of viral infections in multiple sclerosis and other related demyelinating diseases, in: “Multiple Sclerosis”, J. F. Hallpike, C. W. M. Adams, and W. W. Tourtellotte, eds., Williams and Wilkins, Baltimore (1983).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • William A. Sibley
    • 1
  1. 1.Department of NeurologyUniversity of Arizona and University Medical CenterTucsonUSA

Personalised recommendations